Please provide your email address to receive an email when new articles are posted on . The FDA approved expanded labeling for Medtronic’s InterStim II and InterStim Micro sacral neuromodulation ...

Medtronic continues to up its game in sacral neuromodulation. FDA approved InterStim X, the next generation of the company's InterStim portfolio's recharge-free device. Medtronic said implants have ...

Medtronic (MDT) recently announced that it has received a favorable decision with respect to a long-standing patent dispute related to sacral neuromodulation. Specifically, per Medtronic’s press ...

Dublin-based Medtronic plc has filed a PMA supplement with the U.S. FDA for its next-generation, implantable sacral neuromodulation (SNM) device, Interstim Micro, and for its Interstim Surescan MRI ...

DUBLIN, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that its recently FDA-approved InterStim™ Micro neurostimulator for sacral ...

This x-ray of the pelvis shows an electronic nerve-stimulating device in the right iliac fossa. Over 10 months, complete continence was achieved by approximately half of implanted patients. Real-world ...

Competition in the sacral neuromodulation space continues to breed new options for patients with bladder and bowel dysfunction. Irvine, CA-based Axonics now has FDA approval for its recharge-free ...

(HealthDay News) — For women with refractory urgency urinary incontinence, onabotulinumtoxinA injections may help control leakage better than the implanted nerve stimulation device InterStim, ...

Hot on the heels of the U.S. launch of its recharge-free neurostimulation implant to treat incontinence, Axonics is bringing yet another of its sacral neuromodulation (SNM) devices to our neighbors to ...

DUBLIN, Feb. 22, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it received approval from the U.S. Food and Drug Administration (FDA) for ...

SAN JOSE, Calif., June 18, 2025 /PRNewswire/ -- Neuspera ® Medical, Inc., the leading developer of integrated technologies powering the future of neuromodulation, today announced that the U.S. Food ...